Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Main Article Content
Keywords
Ritlecitinib, Adolescent, Alopecia Areata, Integrated Safety, ALLEGRO , long-term, JAK3/TEC family kinase inhibitor
Abstract
Introduction This updated integrated safety analysis evaluated ritlecitinib in adolescents (aged 12-17 years) with alopecia areata (AA) in the ALLEGRO phase 2b/3 study and/or ongoing ALLEGRO-LT phase 3 study.
Methods In ALLEGRO-2b/3, patients with ≥50% scalp hair loss received daily ritlecitinib 30-mg or 50-mg (±4-week 200-mg loading dose), 10-mg, or placebo. In ALLEGRO-LT, de novo patients (≥25% scalp hair loss) received daily ritlecitinib 50-mg with a 4-week 200-mg loading dose and ALLEGRO-2b/3 rollover patients received daily ritlecitinib 50-mg (data cutoff June 25, 2024). Continuation criteria in ALLEGRO-LT required ≥50% improvement in Severity of Alopecia Tool (SALT) score by Month 3 for rollover adolescents and SALT score ≤20 by Month 6 for all adolescents. Safety data were pooled; proportions and incidence rates of adverse events (AEs) are reported for adolescents receiving ritlecitinib 50-mg (50-mg ±4-week 200-mg loading dose) and any-ritlecitinib (any dose, including 50-mg).
Results In the 50-mg group (n=172), median ritlecitinib exposure was 1111.5 days (427.2 total PY); 56.4% of adolescents were exposed for ≥36 months and 24.4% for ≥48. AEs occurred in 144 adolescents (83.7%; 146.3/100 PY) in the 50-mg group. The most common AEs included SARS-CoV-2 positive test (19.8%), acne (19.2%), headache (18.6%), and nasopharyngitis (14.5%). Serious AEs occurred in 10 adolescents (5.8%; 2.3/100 PY). Thirteen adolescents (7.6%; 3.0/100 PY) permanently discontinued due to AEs. Similar results were observed for adolescents in the any-ritlecitinib group (n=181). There were no deaths or incidence of opportunistic infections, herpes zoster, malignancies, cardiovascular, or thromboembolic events.
Conclusion Longer-term use of ritlecitinib for up to ~5 years in adolescents with AA was well-tolerated and demonstrated no new safety signals.
Funding This study was funded by Pfizer Inc.
References
King B, et al. Lancet. 2023;401:1518-1529.
Hordinsky M, et al. Pediatr Dermatol. 2023. doi: 10.1111/pde.15378.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.